Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + docetaxel
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Doxorubicin + docetaxel is a combination chemotherapy regimen consisting of two cytotoxic agents, doxorubicin (an anthracycline antibiotic) and docetaxel (a taxane). Doxorubicin works primarily by intercalating DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells. Docetaxel stabilizes microtubules, preventing their depolymerization during cell division, which results in mitotic arrest and cell death. This combination has demonstrated significant activity in the treatment of metastatic breast cancer and is used as part of various regimens for breast cancer therapy[2][5]. The combination exploits different mechanisms to maximize antitumor efficacy.
- Other names
- docetaxel/doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on doxorubicin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + docetaxel.